Wire · opportunities
J&J's disappointing Q3, RevMed's subgroup data, BMS' 'mixed' results, Caribou's cutback
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 October 2026 · Fusion42 review
Johnson & Johnson beat third-quarter expectations driven by innovative medicines despite medtech underperformance; Bristol Myers Squibb achieved a Phase 3 win for a lung disease drug validating its RayzeBio acquisition but showed mixed trial results; Revolution Medicines' pancreatic cancer drug approval shows better efficacy in certain genetic subgroups; Caribou Biosciences is facing significant cutbacks signaling potential market exit.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You should reassess your exposure to medtech subsegments as innovation overtakes J&J's traditional medtech; Bristol Myers Squibb’s buyout validation offers a new wave of customers for related therapies. Watch for subgroup-specific opportunities in pancreatic cancer treatment from Revolution Medicines. Caribou's cutback warns of tightening funding or shifting priorities in gene editing ventures.
◆ Coverage
1 source · 14 Oct 2026
◆ Related on Wire
◆ Topics